MALT1 inhibitors and uses thereof

US10711036B2 · kind B2 · utility

Assignees

• Cornell University · IT
• DANA-FARBER CANCER INSTITUTE, INC. · US
• Children's Medical Center Corporation · US

Inventors

• Nathanael S. Gray · Boston, US
• David A. Scott · Newton, US
• John Hatcher · Boston, US
• Spandan Chennamadhavuni · Natick, US
• Ari M. Melnick · New York, US
• Lorena Fontan Gabas · New York, US
• Hao Wu · Shanghai, CN
• Qi Qiao · San Diego, US
• Guangyan Du · Brookline, US

Key dates

• Filing date: Aug 26, 2016
• Grant date: Jul 14, 2020
• Expiry date: Aug 26, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).